<DOC>
	<DOCNO>NCT03092076</DOCNO>
	<brief_summary>This study open single center clinical trial healthy Chinese.The objective study clarify pharmacokinetics characteristic antiplatelet effect ticagrelor Chinese investigate impact genotype .</brief_summary>
	<brief_title>The Impact Genotype Pharmacokinetics Antiplatelet Effects Ticagrelor Healthy Chinese</brief_title>
	<detailed_description>This open-label , single-does , nonrandomized study ticagrelor healthy volunteer carry single center . Written inform consent obtain volunteer initiation study . The study approve Research Ethic Committee Guangdong General Hospital . Fifty-one healthy Chinese recruit . Venous blood collect 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 , 24 48h take 180mg ticagrelor orally . Urine collection interval predose 0 2 , 2 4 , 4 6 , 6 9 , 9 12 , 12 16 16 24h dosing . The concentration ticagrelor metabolites analyze use separately validate liquid chromatography technique tandem mass spectrometric detection ( LC-MS/MS ) . Besidesï¼Œthe basic principle population pharmacodynamics ( PPD ) apply evaluate antiplatelet effect . Adenosine diphosphate ( ADP ) -stimulated platelet aggregation assess baseline , 0.5h/1h , 2h , 4h/8h/24h , 48h/3d/5d 7d dosing . The effect genetic variant antiplatelet pharmacokinetic response ticagrelor investigate genome-wide association study ( GWAS ) .</detailed_description>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age : 18 45 year ; 2 . Sex : male female ; 3 . Ethnicity : Chinese ; 4 . Good health evidence result physical examination , vitals sign , electrocardiogram , clinical laboratory test result , exception abnormal value consider clinical significance ; 5 . Written informed consent . 1 . Any condition know interfere absorption , distribution , metabolism excretion drug ; 2 . Intolerance hypersensitivity drug whose mechanism similar ticagrelor ; 3 . Any history take medicine within half month enrollment ; 4 . Any history whole blood transfusion within 2 month , blood element transfusion blood donation within 1 month enrollment ; 5 . Participation clinical study within 3 month enrollment ; 6 . Abuse caffeine ( &gt; 5 units/day ) , alcohol ( &gt; 21 unit /week ) , smoke ( &gt; 10 cigarettes/day ) ; 7 . Positive serology Hbs antigen HIV ; 8 . History coagulation disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>antiplatelet effect</keyword>
	<keyword>single nucleotide polymorphism ( SNP )</keyword>
</DOC>